Idarubicine
Chronic Myelomonocytic Leukemia
Fred Hutchinson Cancer CenterPhase 3Active
BB
66/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 62/ 100
- Competitive Position
- 73/ 100
Competitive context
97 Active assets in the Chronic Myelomonocytic Leukemia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Pevonedistat Takeda | Phase 3 | BB |
Venetoclax Servier Bio-Innovation LLC | Phase 2/3 | BB |
Azacitidine The University of Hong Kong | Phase 3 | BB |
CYCLOSPORIN A Fred Hutchinson Cancer Center | Phase 2 | BB |
Evomela City of Hope Medical Center | Phase 2 | BB |
View all 50 →
Same molecule, other indications
Idarubicine is also rated in:
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
76 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →